SNGX - Soligenix Inc Stock Price, Fair Value and News

0.39USD0.00 (0.00%)Delayed

Market Summary

USD0.390.00

Delayed

0.00%

SNGX Stock Price

View Fullscreen

SNGX RSI Chart

SNGX Valuation

Market Cap

6.2M

Price/Earnings (Trailing)

-0.88

Price/Sales (Trailing)

8.81

EV/EBITDA

-0.27

Price/Free Cashflow

-0.79

SNGX Price/Sales (Trailing)

SNGX Profitability

Operating Margin

9.46%

EBT Margin

-1089.31%

Return on Equity

-912.31%

Return on Assets

-86.99%

Free Cashflow Yield

-126.26%

SNGX Fundamentals

SNGX Revenue

Revenue (TTM)

699.2K

Rev. Growth (Yr)

-54.49%

Rev. Growth (Qtr)

-52.2%

SNGX Earnings

Earnings (TTM)

-7.0M

Earnings Growth (Yr)

-83.09%

Earnings Growth (Qtr)

-5.24%

Breaking Down SNGX Revenue

Last 7 days

-2.5%

Last 30 days

-23.5%

Last 90 days

-43.5%

Trailing 12 Months

-49.8%

How does SNGX drawdown profile look like?

SNGX Financial Health

Current Ratio

1.08

Debt/Equity

3.77

Debt/Cashflow

-2.68

SNGX Investor Care

Shares Dilution (1Y)

94.68%

Diluted EPS (TTM)

-0.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	699.2K	0	0	0
2023	1.0M	996.3K	960.6K	839.4K
2022	864.7K	878.6K	858.5K	948.9K
2021	1.6M	1.3M	869.4K	824.3K
2020	4.4M	3.4M	2.7M	2.4M
2019	5.3M	5.1M	5.0M	4.6M
2018	5.2M	6.0M	5.5M	5.2M
2017	0	8.1M	7.3M	5.4M
2016	0	0	0	0
2015	0	0	0	0
2014	3.2M	4.0M	6.5M	1.5M
2013	3.2M	3.2M	2.8M	3.2M
2012	6.1M	6.4M	2.3M	0
2011	3.0M	4.1M	5.1M	6.2M
2010	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Soligenix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 18, 2022	schaber christopher j	bought	8,866	0.4433	20,000	chairman, ceo and president
May 18, 2022	straube richard	bought	4,000	0.5	8,000	senior vice president and cmo
Dec 17, 2021	schaber christopher j	bought	5,179	0.7399	7,000	chairman, ceo and president
Dec 15, 2021	guarino jonathan l.	bought	700	0.7	1,000	senior vice president and cfo
Dec 14, 2021	schaber christopher j	bought	7,269	0.7269	10,000	chairman, ceo and president
Dec 14, 2021	guarino jonathan l.	bought	7,119	0.7119	10,000	senior vice president and cfo
May 14, 2021	zeldis jerome b	sold	-2,700	0.9002	-3,000	-
May 14, 2021	zeldis jerome b	bought	2,664	0.888	3,000	-
Nov 19, 2019	schaber christopher j	bought	10,016	0.93	10,770	chairman, ceo and president
Nov 19, 2019	zeldis jerome b	bought	1,850	0.925	2,000	-

Which funds bought or sold SNGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-0.19	-571	2,156	-%
May 15, 2024	FIRST WILSHIRE SECURITIES MANAGEMENT INC	unchanged	-	-4,000	14,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-3.00	12.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	2.83	-947	4,181	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	6,861	6,861	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	8.5	-1,246	7,639	-%
May 15, 2024	NOMURA HOLDINGS INC	new	-	18,000	18,000	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-13,435	-	-%
May 14, 2024	NewEdge Advisors, LLC	reduced	-93.75	-34.00	2.00	-%
May 13, 2024	UBS Group AG	new	-	857	857	-%

Are Funds Buying or Selling SNGX?

Are funds buying SNGX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNGX

No. of Funds

Unveiling Soligenix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 06, 2020	altamont pharmaceutical holdings, llc	2.6%	678,338	SC 13G/A
Apr 23, 2020	altamont phamaceutical holdings, llc	5.0%	1,278,338	SC 13G/A
Feb 07, 2020	act capital management, lllp	5.6%	1,221,499	SC 13G/A

Recent SEC filings of Soligenix Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 17, 2024	DEFA14A	DEFA14A
May 15, 2024	DEFA14A	DEFA14A
May 10, 2024	424B3	Prospectus Filed
May 10, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	PRE 14A	PRE 14A
Apr 19, 2024	424B4	Prospectus Filed

Peers (Alternatives to Soligenix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Soligenix Inc News

Latest updates

Soligenix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-52.2%	117,029	244,812	130,440	206,929	257,178	366,068	166,140	228,640	188,063	275,653	186,198	214,824	147,593	320,795	608,811	505,288	924,552	685,261	1,254,904	1,544,964	1,144,788
Cost Of Revenue	-47.2%	117,029	221,546	110,441	184,021	226,040	135,865	129,440	193,304	92,213	235,698	166,265	204,317	122,360	241,464	386,641	363,339	829,506	587,224	965,453	1,086,814	927,924
Gross Profit	-100.0%	-	23,266	19,999	22,908	31,138	230,203	36,700	35,336	95,850	39,955	19,933	10,507	25,233	79,332	222,170	141,949	95,046	98,037	289,451	458,150	216,864
Operating Expenses	-2.0%	2,117,091	2,161,137	1,799,055	1,653,232	2,181,827	3,800,181	3,117,944	3,430,632	4,288,236	4,551,738	3,384,844	2,999,166	2,258,840	5,565,399	2,034,947	2,955,821	8,568,838	3,407,505	3,056,050	2,623,041	2,516,927
S&GA Expenses	-100.0%	-	1,383,603	973,040	890,533	1,235,376	1,442,394	1,326,249	1,382,793	2,541,468	1,849,583	1,147,279	1,062,558	949,318	1,905,975	768,420	785,776	868,667	1,048,362	789,251	769,091	874,209
R&D Expenses	40.8%	1,095,040	777,534	826,015	762,699	946,451	2,357,787	1,791,695	2,047,839	1,746,768	2,702,155	2,237,565	1,936,608	1,309,522	3,659,424	1,266,527	2,170,045	2,700,171	2,359,143	2,266,799	1,853,950	1,642,718
EBITDA Margin	-17.7%	-10.32	-8.76	-8.85	-10.04	-11.72	-14.82	-16.84	-17.26	-17.12	-16.08	-17.13	-9.96	-8.00	-7.83	-	-	-	-	-	-	-
Interest Expenses	0%	64,047	64,047	63,351	211,170	213,490	213,490	211,170	208,850	223,901	768,836	-216,800	-214,750	-213,505	-35,332	486	2,017	21,947	-	-	-	-
Income Taxes	100.0%	-	-606,606	-	-	-1,161,197	-	-1,154,935	-1,154,935	-	431,305	-864,742	-864,742	2,132	-	-	-	-836,893	-	-	-	-610,676
Earnings Before Taxes	21.1%	-1,915,327	-2,426,501	-1,662,702	-1,612,024	-2,207,306	-3,753,555	-3,309,003	-3,541,695	-4,349,021	-4,703,876	-3,587,551	-2,761,810	-2,362,478	-5,540,265	-1,790,160	-2,776,763	-8,418,227	-2,871,661	-2,720,783	-2,123,521	-2,250,303
EBT Margin	-15.6%	-10.89	-9.42	-9.61	-10.92	-12.58	-15.76	-18.52	-18.42	-17.81	-16.28	-16.39	-9.64	-7.88	-7.85	-	-	-	-	-	-	-
Net Income	-5.2%	-1,915,327	-1,819,895	-1,662,702	-1,612,024	-1,046,109	-3,753,555	-3,309,003	-2,386,760	-4,349,021	-4,703,876	-3,587,551	-1,897,068	-2,362,478	-5,540,265	-1,790,160	-2,776,763	-7,581,334	-2,871,661	-2,720,783	-2,123,521	-1,639,627
Net Income Margin	-37.0%	-10.03	-7.32	-8.41	-9.76	-10.31	-14.54	-17.18	-17.10	-16.81	-15.23	-15.40	-8.97	-7.88	-7.50	-	-	-	-	-	-	-
Free Cashflow	26.6%	-1,342,482	-1,828,213	-2,686,316	-1,923,327	-2,166,253	-3,627,141	-3,254,977	-2,528,060	-3,238,843	-3,055,354	-3,040,119	-1,658,920	-3,985,227	-4,124,955	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-17.7%	8,058	9,797	11,303	13,826	11,102	14,280	17,947	21,312	23,675	26,870	29,718	29,610	31,552	19,891	13,250	12,261	9,848	7,775	8,332	9,193	9,521
Current Assets	-17.8%	7,818	9,507	10,972	13,471	10,722	13,853	17,493	20,826	23,474	26,570	29,445	29,353	31,280	19,467	12,730	11,977	9,569	7,493	8,010	8,812	9,128
Cash Equivalents	-16.0%	7,092	8,446	10,299	13,161	10,266	13,360	16,866	20,158	22,876	26,044	28,867	28,980	30,542	18,677	11,343	11,168	7,203	5,421	6,552	6,986	7,200
Net PPE	-13.3%	10.00	12.00	14.00	15.00	17.00	18.00	22.00	26.00	28.00	22.00	14.00	17.00	20.00	24.00	28.00	33.00	38.00	36.00	10.00	12.00	16.00
Liabilities	0.2%	7,290	7,275	7,082	8,026	14,489	16,751	16,915	17,107	17,090	16,147	14,663	14,014	14,234	16,149	5,845	6,230	6,333	6,318	5,654	5,557	4,240
Current Liabilities	17.2%	7,211	6,152	5,522	5,758	11,377	16,517	9,666	8,840	7,224	6,291	4,796	4,125	4,301	6,081	5,536	5,996	6,329	6,312	5,634	5,500	4,148
Long Term Debt	-100.0%	-	1,011	1,416	2,094	2,908	-	6,887	7,877	9,866	9,856	9,846	9,835	9,824	9,860	-	-	-	-	-	-	-
LT Debt, Current	33.2%	2,996	2,250	1,500	750	6,000	9,898	3,000	2,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-69.5%	768	2,522	4,221	5,800	-3,387	-2,470	1,032	4,206	6,584	10,723	15,055	15,596	17,319	3,742	7,405	6,031	3,515	1,457	2,678	3,636	5,282
Retained Earnings	-0.8%	-227,619	-225,704	-223,884	-222,221	-220,609	-219,563	-215,809	-212,500	-210,114	-205,765	-201,061	-197,473	-195,576	-193,214	-187,673	-185,883	-183,106	-175,525	-172,653	-169,933	-167,809
Additional Paid-In Capital	0.1%	228,353	228,194	228,071	228,006	217,207	217,065	216,773	216,653	216,531	216,443	216,024	213,062	212,891	196,950	195,059	191,923	186,625	177,006	175,326	173,558	173,076
Accumulated Depreciation	-100.0%	-	121	120	118	117	115	112	107	172	168	164	161	-	155	-	-	-	-	-	-	-
Shares Outstanding	1.4%	10,524	10,378	10,378	9,842	2,930	2,909	2,872	2,867	2,861	2,858	2,713	2,672	2,455	-	-	-	-	-	-	-	-
Float	-	-	-	-	6,847	-	-	-	25,735	-	-	-	39,976	-	-	-	57,300	-	-	-	9,584	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	26.6%	-1,342	-1,828	-2,686	-1,923	-2,166	-3,627	-3,254	-2,528	-3,238	-3,055	-3,040	-1,658	-3,985	-4,124	-2,990	-1,643	-2,695	-2,643	-2,057	-515	-2,293
Share Based Compensation	-57.5%	60.00	141	65.00	90.00	74.00	113	71.00	72.00	78.00	106	80.00	81.00	95.00	199	67.00	81.00	64.00	142	82.00	73.00	80.00
Cashflow From Investing	-	-	-	-	-	-	-	-	-3.25	-9.82	-	-	-	-	-	-	-	-7.15	-30.21	-	-	-
Cashflow From Financing	80.5%	-8.99	-46.18	-175	4,817	-931	-	-	-	-	251	2,863	89.00	15,856	11,435	3,109	5,618	4,516	1,559	1,637	304	505

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SNGX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenues	$ 117,029	$ 257,178
Cost of revenues	(117,029)	(226,040)
Gross profit		31,138
Operating expenses:
Research and development	1,095,040	946,451
General and administrative	1,022,051	1,235,376
Total operating expenses	2,117,091	2,181,827
Loss from operations	(2,117,091)	(2,150,689)
Other income (expense):
Foreign currency transaction gain (loss)	1,209	(366)
Interest income (expense), net	28,842	(103,568)
Research and development incentives	6,331	6,448
Other income		40,869
Change in fair value of convertible debt	165,382
Total other income (expense)	201,764	(56,617)
Net loss before income taxes	(1,915,327)	(2,207,306)
Income tax benefit		1,161,197
Net loss applicable to common stockholders	$ (1,915,327)	$ (1,046,109)
Basic net loss per share (in Dollars per share)	$ (0.18)	$ (0.36)
Diluted net loss per share (in Dollars per share)	$ (0.18)	$ (0.36)
Basic weighted average common shares outstanding (in Shares)	10,521,233	2,914,929
Diluted weighted average common shares outstanding (in Shares)	10,521,233	2,914,929
Grant revenue
Total revenues	$ 117,029	$ 257,178

SNGX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 7,091,548	$ 8,446,158
Contracts and grants receivable	117,029
Unbilled revenue		171,254
Research and development incentives receivable, current	25,253	23,894
Deferred issuance cost	132,681
Prepaid expenses and other current assets	451,876	866,014
Total current assets	7,818,387	9,507,320
Security deposit	22,777	22,777
Office furniture and equipment, net	10,339	11,927
Right-of-use lease assets	200,569	229,834
Research and development incentives receivable, net of current portion	6,313	25,468
Total assets	8,058,385	9,797,326
Current liabilities:
Accounts payable	1,436,728	1,111,226
Accrued expenses	2,602,665	2,418,002
Accrued compensation	50,216	251,115
Lease liabilities, current	125,143	121,765
Convertible debt	2,996,136	2,250,000
Total current liabilities	7,210,888	6,152,108
Non-current liabilities:
Convertible debt		1,010,934
Lease liabilities, net of current portion	79,125	111,862
Total liabilities	7,290,013	7,274,904
Commitments and contingencies (Note 6)
Shareholders' equity:
Preferred stock, 350,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $.001 par value; 75,000,000 shares authorized; 10,524,437 and 10,378,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	10,524	10,378
Additional paid-in capital	228,353,208	228,193,977
Accumulated other comprehensive income	24,143	22,243
Accumulated deficit	(227,619,503)	(225,704,176)
Total shareholders' equity	768,372	2,522,422
Total liabilities and shareholders' equity	$ 8,058,385	$ 9,797,326

About Soligenix Inc

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

CEO	Dr. Christopher J. Schaber Ph.D.
WEBSITE	soligenix.com
INDUSTRY	Biotechnology
EMPLOYEES	13

Soligenix Inc Frequently Asked Questions

What is the ticker symbol for Soligenix Inc? What does SNGX stand for in stocks?

SNGX is the stock ticker symbol of Soligenix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Soligenix Inc (SNGX)?

As of Fri May 17 2024, market cap of Soligenix Inc is 6.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNGX stock?

You can check SNGX's fair value in chart for subscribers.

What is the fair value of SNGX stock?

You can check SNGX's fair value in chart for subscribers. The fair value of Soligenix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Soligenix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Soligenix Inc a good stock to buy?

The fair value guage provides a quick view whether SNGX is over valued or under valued. Whether Soligenix Inc is cheap or expensive depends on the assumptions which impact Soligenix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNGX.

What is Soligenix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SNGX's PE ratio (Price to Earnings) is -0.88 and Price to Sales (PS) ratio is 8.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNGX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Soligenix Inc's stock?

In the past 10 years, Soligenix Inc has provided -0.339 (multiply by 100 for percentage) rate of return.